A detailed history of Jane Street Group, LLC transactions in Incyte Corp stock. As of the latest transaction made, Jane Street Group, LLC holds 146,748 shares of INCY stock, worth $10.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
146,748
Previous 1,490,359 90.15%
Holding current value
$10.4 Million
Previous $90.3 Million 89.26%
% of portfolio
0.0%
Previous 0.1%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$57.33 - $68.61 $77 Million - $92.2 Million
-1,343,611 Reduced 90.15%
146,748 $9.7 Million
Q2 2024

Aug 14, 2024

BUY
$51.18 - $63.75 $65.1 Million - $81 Million
1,271,135 Added 579.83%
1,490,359 $90.3 Million
Q1 2024

May 15, 2024

SELL
$56.55 - $66.59 $9.56 Million - $11.3 Million
-169,028 Reduced 43.54%
219,224 $12.5 Million
Q4 2023

Feb 14, 2024

BUY
$52.16 - $64.19 $16.3 Million - $20 Million
311,986 Added 409.08%
388,252 $24.4 Million
Q3 2023

Nov 14, 2023

BUY
$57.77 - $65.93 $2.3 Million - $2.62 Million
39,812 Added 109.21%
76,266 $4.41 Million
Q2 2023

Aug 14, 2023

SELL
$60.95 - $75.51 $2.1 Million - $2.6 Million
-34,412 Reduced 48.56%
36,454 $2.27 Million
Q1 2023

May 15, 2023

SELL
$70.23 - $86.01 $2.1 Million - $2.57 Million
-29,881 Reduced 29.66%
70,866 $5.12 Million
Q4 2022

Feb 14, 2023

SELL
$67.18 - $84.11 $1.39 Million - $1.74 Million
-20,714 Reduced 17.05%
100,747 $8.09 Million
Q3 2022

Nov 14, 2022

BUY
$66.18 - $82.86 $69,158 - $86,588
1,045 Added 0.87%
121,461 $8.1 Million
Q2 2022

Aug 16, 2022

BUY
$66.18 - $83.18 $1.79 Million - $2.26 Million
27,113 Added 29.06%
120,416 $9.15 Million
Q1 2022

May 17, 2022

BUY
$66.02 - $79.71 $132,832 - $160,376
2,012 Added 2.2%
93,303 $7.41 Million
Q4 2021

Feb 15, 2022

BUY
$63.34 - $74.11 $1.09 Million - $1.27 Million
17,179 Added 23.18%
91,291 $6.7 Million
Q3 2021

Nov 16, 2021

SELL
$68.67 - $84.02 $709,086 - $867,590
-10,326 Reduced 12.23%
74,112 $5.1 Million
Q2 2021

Aug 16, 2021

BUY
$79.87 - $87.53 $3.57 Million - $3.91 Million
44,694 Added 112.45%
84,438 $7.1 Million
Q1 2021

May 18, 2021

BUY
$76.02 - $100.5 $2.16 Million - $2.86 Million
28,443 Added 251.69%
39,744 $3.23 Million
Q4 2020

Feb 17, 2021

BUY
$80.74 - $97.7 $365,267 - $441,994
4,524 Added 66.76%
11,301 $983,000
Q3 2020

Nov 17, 2020

BUY
$85.07 - $109.69 $147,086 - $189,654
1,729 Added 34.25%
6,777 $608,000
Q2 2020

Aug 17, 2020

SELL
$74.18 - $108.93 $1.2 Million - $1.77 Million
-16,207 Reduced 76.25%
5,048 $525,000
Q1 2020

May 15, 2020

SELL
$63.18 - $85.97 $1.27 Million - $1.73 Million
-20,109 Reduced 48.61%
21,255 $1.56 Million
Q4 2019

Feb 14, 2020

BUY
$73.04 - $95.72 $2.28 Million - $2.99 Million
31,268 Added 309.71%
41,364 $3.61 Million
Q3 2019

Nov 14, 2019

SELL
$72.82 - $86.52 $742,836 - $882,590
-10,201 Reduced 50.26%
10,096 $749,000
Q2 2019

Aug 15, 2019

SELL
$73.52 - $88.7 $666,311 - $803,888
-9,063 Reduced 30.87%
20,297 $1.72 Million
Q1 2019

May 16, 2019

SELL
$63.56 - $88.17 $171,993 - $238,588
-2,706 Reduced 8.44%
29,360 $2.53 Million
Q4 2018

Feb 15, 2019

BUY
$58.5 - $69.94 $926,523 - $1.11 Million
15,838 Added 97.6%
32,066 $2.04 Million
Q3 2018

Nov 14, 2018

BUY
$61.75 - $74.23 $222,670 - $267,673
3,606 Added 28.57%
16,228 $1.12 Million
Q2 2018

Aug 15, 2018

SELL
$60.85 - $83.98 $783,382 - $1.08 Million
-12,874 Reduced 50.49%
12,622 $846,000
Q1 2018

May 15, 2018

SELL
$83.06 - $100.98 $2.47 Million - $3 Million
-29,753 Reduced 53.85%
25,496 $2.13 Million
Q4 2017

Feb 15, 2018

BUY
$93.56 - $116.6 $2.43 Million - $3.03 Million
25,991 Added 88.83%
55,249 $5.23 Million
Q3 2017

Nov 14, 2017

BUY
$109.15 - $138.27 $3.19 Million - $4.05 Million
29,258
29,258 $3.42 Million

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $15.8B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.